Summary & Overview
HCPCS J9074: Cyclophosphamide Injection, 5 mg
HCPCS Level II code J9074 designates a 5 mg unit of cyclophosphamide (Sandoz) for injection, a commonly used alkylating agent in oncology and certain autoimmune indications. Nationally, accurate coding for physician-administered drugs like cyclophosphamide matters for clinical documentation, pharmacy operations, and payer reimbursement pathways.
This analysis covers major national payers: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, coding and billing considerations for drug units, and the clinical context in which J9074 is typically used. The publication highlights benchmarks for utilization and payment where available, notes relevant policy updates that affect billing for physician-administered drugs, and summarizes common service settings and documentation priorities.
The report is intended for revenue cycle leaders, oncology practice managers, and policy analysts seeking a concise reference on how J9074 is applied across clinical and payer environments. Data not available in the input will be identified as such in dedicated sections.
Billing Code Overview
HCPCS Level II code J9074 represents an injection of cyclophosphamide (Sandoz), 5 mg. This code documents administration of the specified antineoplastic/immune-modulating agent in a measured 5 mg unit.
Service Type: Drug administration (intravenous or injectable antineoplastic)
Typical Site of Service: Outpatient infusion centers, hospital outpatient departments, physician offices, and other settings where injectable chemotherapy or immunosuppressive therapy is administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult oncology patient receiving intravenous cyclophosphamide for treatment of a hematologic malignancy (for example, non-Hodgkin lymphoma) or as part of an immunosuppressive regimen for severe autoimmune disease (for example, systemic lupus erythematosus with organ involvement). The medication is billed as J9074 per 5 mg vial. A typical workflow: patient arrives to an outpatient infusion center or hospital infusion unit, nursing performs pre-infusion assessment (vital signs, lab review for neutrophil/platelet counts, renal function), intravenous access is established, chemotherapy order verified by pharmacy, dose calculated (mg/kg or BSA) and compounded under sterile conditions, antiemetic premedication given as indicated, J9074 doses administered intravenously over the prescribed infusion time, patient observed for acute infusion reactions, post-infusion instructions provided, and documentation completed in the medical record. Typical sites of service include an outpatient infusion center, hospital outpatient department, or inpatient ward when given during admission. Common patient modifiers relevant to documentation include those reflecting treatment complications, discontinuation, or drug wastage.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug discarded/not administered to any patient |